💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

GS Paper: GS3-17.Awareness in the fields of IT, Space, Computers, Robotics, Nano-technology, Bio-technology and issues relating to Intellectual Property Rights.

  • India’s Traditional Knowledge Digital Library (TKDL) which has a database containing formatted information on more than 2 million medicinal formulations is proving a powerful weapon in the country’s fight against erroneous patents. Discuss the pros and cons making this database publicly available under open-source licensing

  • What do you understand by ‘Standard Positioning Systems’ and ‘Protection Positioning Systems’ in the GPS era? Discuss the advantages India perceives from its ambitious IRNSS programme employing just seven satellites.

  • What are the areas of prohibitive labour that can be sustainably managed by robots? Discuss the initiatives that can propel research in premier research institutes for substantive and gainful innovation.

  • Discuss India’s achievements in the field of Space Science and Technology. How the application of this technology has helped India in its socio-economic development?

  • Why is nanotechnology one of the key technologies of the 21st century? Describe the salient features of Indian Government’s Mission on Nanoscience and Technology and the scope of its application in the development process of the country.

  • India has achieved remarkable successes in unmanned space missions including the Chandrayaan and Mars Orbitter Mission, but has not ventured into manned space mission, both in terms of technology and logistics? Explain critically.

  • Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?

    Biotechnology involves using living organisms and biological systems to develop useful products and processes. India is now among the world’s top 12 biotechnology hubs.

    Activity in the field of Biotechnology in India

    Robust Government Policy: Initiatives like the National Biotechnology Development Strategy 2021-2025 have provided a roadmap for a $150 billion bio-economy by 2025.

    Institutional Framework: The Department of Biotechnology (DBT) and BIRAC provide critical seed funding and mentorship to over 5,000 startups.

    Cost-Effective R&D: India offers a significant cost advantage (nearly 33% lower) in R&D and manufacturing compared to developed nations, attracting Global Capability Centers (GCCs).

    Vast Biodiversity and Genetic Pool: India’s diverse climatic zones and ethnic genetic diversity provide a massive “natural laboratory” for genomic research and agricultural biotech.

    Human Capital: A steady influx of STEM graduates (over 2 million annually) provides the technical workforce required for high-end lab work and clinical trials.

    Infrastructure Growth: The establishment of specialized Biotech Parks offers “plug-and-play” facilities for rapid scaling. Eg- Genome Valley in Hyderabad.

    FDI Liberalization: 100% Foreign Direct Investment (FDI) is permitted under the automatic route for greenfield projects, boosting capital infusion.

    Digital Integration: The use of AI and Big Data in bioinformatics, supported by the National Supercomputing Mission has accelerated drug discovery and protein folding research.

    Pandemic Legacy: The successful indigenous development of vaccines (e.g., Covaxin) proved India’s “Proof of Concept” to the world, triggering massive reinvestment in the sector.

    Activity benefitting the field of Biopharma

    Global Vaccine Leadership: India now supplies approximately 60% of the world’s vaccines, earning the title Pharmacy of the World.

    Increase Economical Value: The Indian bioeconomy reached an estimated $130-$165.7 billion in 2024, with projections to reach $300 billion by 2030.

    Shift to Biosimilars: Biotechnology has enabled India to move beyond simple generics to complex Biosimilars. India has the highest number of biosimilars approved globally.

    Precision Medicine: Allowed biopharma companies to develop targeted therapies for cancer and rare genetic disorders tailored to the Indian populations

    Clinical Trial Hub: Improved regulatory frameworks such as New Drugs and Clinical Trial Rules, 2019 and biotech expertise have made India a preferred destination for multi-centric global clinical trials.

    Reduced Import Dependency: Local production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) through fermentation technology is reducing reliance on imports.

    Innovation in Biologics: Companies like Zydus Cadila and Dr. Reddy’s are now shifting from “imitative” to “innovative” R&D, focusing on novel biologics for autoimmune diseases.

    Diagnostics Revolution: The biotech boom led to the rapid development of low-cost, molecular diagnostic kits such as RT-PCR, CRISPR-based ‘Feluda’ tests, improving healthcare penetration.

    Major challenges

    High Capital Intensity: Developing a single biosimilar costs $100-250 million, deterring smaller Indian firms from competing.

    Complex Manufacturing Requirements: Biologics require ultra-pure environments, even a 1°C temperature shift can spoil entire production batches.

    Innovation Deficit: India still invests only 7-8% of revenue in R&D compared to 20%+ by global innovators.

    Skill Gap in Advanced Tech: Shortage of professionals trained in bioinformatics, transcriptomics, and computational biology slows down innovation.

    Global Intellectual Property (IP) Conflicts: Navigating the “patent thickets” of global biopharma giants remains a major legal challenge for biosimilars.

    Infrastructure Deficit in NAMs: Lack of standardized, industry-ready laboratories for non-animal methodologies across the country.

    Supply Chain Fragility: India remains dependent on imported raw materials like specialized cell culture media for biotech production.

    Way forward

    Strengthening Regulatory Cadre: Creating a dedicated “Scientific Review Cadre” within CDSCO to match global approval timelines.

    Expanding Clinical Trial Capacity: Establishing a national network of 1,000 accredited clinical trial sites to accelerate drug development.

    Investing in Biofoundries under BioE3 Policy to provide common infrastructure for startups to test and scale.

    Academic-Industry Collaboration: Upgrading seven NIPERs into “Centers of Excellence” for translational research and high-end skilling.

    Strategic Use of Free Trade Agreements: Leveraging FTAs with the EU and UK to harmonize quality standards and boost exports.

    By bridging the gap between laboratory research and commercial biopharma, India is moving toward Atmanirbhar Bharat in healthcare.

  • How can biotechnology improve the living standards of farmers?

    Karoly Ereky coined the term “Biotechnology” in 1919 to describe the fusion of biological and technological processes aimed at enhancing life on Earth. For agriculture, biotechnology has emerged as a significant boon, elevating crop quality and yield through innovative approaches.

    Role of Biotechnology in Improving Living Standards of Farmers

    Provides disease-free planting material through tissue culture. Eg- Tissue culture banana (G-9 cultivar) increases yields by 30-40%.

    Enhances crop yields through high-yielding and hybrid varieties. Eg- “Swarna Sub-1” flood-tolerant rice and “DRR Dhan 42” drought-tolerant rice.

    Reduces pesticide cost through pest-resistant GM crops. Eg- Bt cotton reduced pesticide use by 40-60%.

    Lowers fertilizer expenses using biofertilisers. Eg- Rhizobium and Azotobacter cuts nitrogen fertilizer requirement in pulses/oilseeds.

    Increases resilience to climate shocks with stress-tolerant seeds. Eg- Drought Tolerant High-Yielding Chickpea Variety “SAATVIK (NC 9)”

    Reduces post-harvest losses using improved shelf-life varieties. Eg- Delayed-ripening tomato (Arka Rakshak) reduces spoilage.

    Nutritional security through biofortified crops. Eg- Iron-rich pearl millet (ICMH 1202).

    Kisan-Kavach: An anti-pesticide suit designed to combat the threat of pesticide-induced toxicity in agricultural settings.

    Enables diversification into high-value crops. Eg- Tissue-culture strawberries (“Chandler”) in Himachal Pradesh.

    Boosts dairy income through microbial feed supplements. Eg- Yeast-based probiotics increase milk yield by 8-12%.

    Enhances fishery productivity using improved seed varieties. Eg- Jayanti Rohu shows 17-20% higher growth rates.

    Generates rural employment – Eg- Tissue culture labs and biofertiliser units run through FPOs in Telangana.

    Supports women-led microenterprises – Eg- SHGs in Tamil Nadu producing vermicompost.

    Challenges

    Regulatory Complexity: Approval processes for GMOs and biotech tools are lengthy. Eg- delay in approval of GM Mustard (DMH-11)

    Public skepticism about GMOs. Eg- opposition to Bt Brinjal.

    Environmental and Ethical Concerns: Gene flow to non-target species, biodiversity risks, and ethical considerations around gene editing. Eg- concerns over “playing God”

    Access and Equity: High development costs and IP protections limit access for smallholders.

    Health concerns – Eg- StarLink corn incident (2000) – animal-feed-only GM corn entered the human food chain.

    Limited private sector participation – Eg- Policies such as the Cotton Seed Price Control Order (2015) and mandatory tech transfer provisions have discouraged private R&D

    Illegal Cultivation and biosafety risks – Eg- HT-Bt cotton is illegally cultivated on up to 25% of cotton acreage in India

    Declining Cotton Productivity – Yields have fallen from 566 kg/ha (2013-14) to 436 kg/ha (2023-24), far below China and Brazil’s 1,800-1,900 kg/ha.

    Rising Import Dependence – India has shifted from net exporter to net importer, with cotton imports reaching $0.4 billion in 2024-25.

    Undermining seed sovereignty due to intellectual property rights. Eg – Monsanto-Mahyco Bt cotton disputes

    Way Forward

    Science-Based Regulation- Ensure transparent field trials, publicly accessible data and independent monitoring,

    Promote public-private partnerships in biotech research and support region-specific GM crops

    Implement robust GM labeling and enforce strict action against illegal cultivation and counterfeit seeds.

    Prioritise biofortified GM crops such as Golden Rice, iron-rich pulses, and zinc-rich wheat to combat micronutrient deficiencies

    Effective implementation of BioE3 mission can help realise Vajpayee’s vision of Biotech for Bharat – “What IT is for India, BT is for Bharat”

  • What is India’s plan to have its own space station and how will it benefit our space programme?

    A space station is a habitable, long-term orbital laboratory for scientific research. India’s plan to build the Bharatiya Antariksha Station (BAS) represents a pivotal shift from short-duration missions to a sustained human presence in space.

    India’s Plan for Bharatiya Antariksha Station (BAS)

    The BAS is envisioned as a modular space station positioned in Low Earth Orbit (LEO) at an altitude of approximately 400-450 km.

    Modular Architecture: The station will consist of five modules launched in phases. The station’s total weight is estimated at 52 tonnes upon completion.

    Timeline:

    2028: Target for the launch of the first module, BAS-01 (Base Module).

    2028-2035: Sequential launch and docking of the remaining four modules.

    2035: Targeted year for the station to become fully operational.

    Technical Specifications: It is designed to accommodate a nominal crew of 3 to 4 astronauts for durations of 3 to 6 months, with a maximum capacity of 6 during crew handovers.

    The plan involves mastering Rendezvous and Docking (SpaDeX), advanced Environmental Control and Life Support Systems (ECLSS), and robotic arm operations.

    Benefits to India’s Space Programme

    Scientific

    Microgravity Research Platform: It provides a permanent laboratory for long-term experiments in biotechnology, materials science, and pharmaceuticals that cannot be replicated on Earth.

    Advanced Life Support Systems (ECLSS): Mastering the recycling of air and water is essential for sustaining life; BAS serves as the ultimate testbed for these “closed-loop” technologies.

    Technological

    Rendezvous and Docking Maturity: Successful operation requires perfecting the SpaDeX (Space Docking Experiment) technology, a critical skill for any future lunar or interplanetary assembly.

    Gateway to the Moon (2040): The station acts as a training ground for the Bharatiya Antariksha Yatri, preparing them for the planned 2040 Lunar Landing.

    In-Orbit Refueling and Servicing: BAS will pioneer technologies to refuel satellites in orbit, potentially extending the life of multi-billion dollar assets and reducing space debris.

    International

    Strategic Autonomy: Having an independent station ensures India is not dependent on foreign platforms for sensitive research or strategic orbital maneuvers.

    Geopolitical Leadership: It cements India’s role as a leader in the Global South, offering a potential platform for collaborative missions with nations lacking independent space access.

    Economic

    8. Income for ISRO by leasing out experiments, taking astronauts of other countries.

    9. Boosting space industry in India.

    10. Promotion of space tourism in India.

    The Bharatiya Antariksha Station is the cornerstone of India’s “Space Vision 2047.”

  • How is the government of India protecting traditional knowledge of medicine from patenting by pharmaceutical companies?

    India’s traditional medicinal knowledge includes thousands of formulations and approximately 45,000 plant species, but faces biopiracy threats from multinational companies patenting indigenous resources without consent or compensation.

    Government Initiatives to Protect Traditional Knowledge

    Traditional Knowledge Digital Library (TKDL):

    Translates ancient medicinal texts from Sanskrit, Urdu, Tamil, Persian and other languages into English, French, German, Spanish, and Japanese for global patent examiners.

    Contains over 4.48 lakh formulations, including Ayurveda, Unani, Siddha, Sowa Rigpa, and Yoga knowledge systems.

    CSIR-TKDL actively files pre-grant oppositions and third-party observations; 283 patent applications were refused, amended, or withdrawn using TKDL evidence.

    The Biological Diversity Act, 2002: Mandates that any foreign individual or commercial entity seeking to use India’s biological resources or traditional knowledge must obtain prior approval from NBA.

    National Biodiversity Authority: NBA is a statutory body implementing the Biological Diversity Act, 2002 to protect India’s biological resources and traditional knowledge.

    People’s Biodiversity Register (PBR): Administered by the NBA, PBR serves as a formal tool for recording and maintaining comprehensive localized data on biological resources and their medicinal uses.

    Access and Benefit Sharing (ABS) agreements:

    Companies using Indian bio-resources must share royalties or benefits with the National Biodiversity Authority.

    These funds support local Biodiversity Management Committees and tribal communities.

    The Patents Act, 1970:

    States that an invention which is traditional knowledge, or an aggregation or duplication of known properties of traditionally known components, is not patentable.

    Mandates disclosure of the source and geographical origin of biological materials used in patents, with details shared with the NBA.

    Protection of Plant Varieties and Farmers’ Rights (PPV&FR) Act, 2001: Protects the rights of local communities and farmers over their traditional crop and medicinal plant varieties.

    By safeguarding indigenous medical heritage through the NBA and TKDL, India directly advances SDG 3 (Good Health and Well-being) and SDG 15 (Life on Land) while protecting local community rights.